Clinical trials: Interleukin
Psoriasis
A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
The primary purpose of this study is to evaluate the effectiveness and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- PHOENIX1 (NCT00267969)
- Testing
- ustekinumab
- Where
- 42 sites in United States, Belgium and 1 more
- Volunteers
- 766 people
- Sponsor
- Centocor Research & Development, Inc.
Bullous Pemphigoid, Pemphigoid
Ixekizumab in the Treatment of Bullous Pemphigoid
Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin…
- Trial name
- NCT03099538
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
The aim of this study is to demonstrate the efficacy and to evaluate the safety, pharmacokinetics (PK) and immunogenicity of anakinra in patients with newly diagnosed Still's disease, including SJIA (Systemic juvenile idiopathic…
- Trial name
- anaSTILLs (NCT03265132)
- Testing
- anakinra
- Where
- 39 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Swedish Orphan Biovitrum
Leukemia, Pediatric Cancer
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
The goal of this clinical research study is to learn if transferring the donor's NK cells, in combination with an antibody called epratuzumab and low-dose interleukin (IL-2), into your body can be done safely.
- Trial name
- NCT00941928
- Testing
- Epratuzumab, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well erlotinib works in treating women undergoing surgery for stage I…
- Trial name
- NCT00503841
- Testing
- erlotinib hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Systemic Lupus Erythematosus
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
- Trial name
- ISLAND-SLE (NCT04433585)
- Testing
- LY3471851
- Where
- 112 sites in United States, Argentina and 17 more
- Volunteers
- 291 people
- Sponsor
- Nektar Therapeutics
Alcoholic Hepatitis
IL-1 Signal Inhibition in Alcoholic Hepatitis
Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption.
- Trial name
- ISAIAH (NCT03775109)
- Testing
- Canakinumab 150mg/ml solution for injection
- Where
- 16 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- Imperial College London
Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis
The purpose of this study is to see if tocilizumab is safe and effective for treating systemic onset Juvenile Idiopathic Arthritis (soJIA).
- Trial name
- NCT00868751
- Testing
- tocilizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tufts Medical Center
COVID-19
Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)
This is a single center, randomized, double-blind, placebo-controlled, exploratory phase II study enrolling 60 patients. We propose the administration of a blinded dose of an investigational product (IP) (clazakizumab or placebo…
- Trial name
- NCT04348500
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cedars-Sinai Medical Center
Any Advanced Solid Tumors, Triple Negative Breast Cancer
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: Safety and tolerability of NT-I7 in combination with pembrolizumab Maximum Tolerated Dose (MTD) and/or the…
- Conditions
- Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04332653
- Testing
- NT-I7, pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 215 people
- Sponsor
- NeoImmuneTech
Hepatitis C, Chronic
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
This multicenter study will evaluate the correlation of interleukin 28B (IL28B) genotypes with disease characteristics and demographics in treatment-naïve and treatment-experienced chronic hepatitis C patients, including patients…
- Trial name
- NCT01675427
- Testing
- Interleukin 28B testing
- Where
- 210 sites in United States, Argentina and 29 more
- Volunteers
- 4,766 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
Low Dose IL-2 for Ulcerative Colitis
The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe ulcerative colitis.
- Trial name
- NCT02200445
- Testing
- Interleukin-2 (aldesleukin).
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Scott B. Snapper, MD PHD
Acute Gouty Arthritis
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis
The purpose of this study is to evaluate how anakinra relieves pain for patients with acute gout that cannot take non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine.
- Trial name
- anaGO (NCT03002974)
- Testing
- Anakinra 100 mg, Triamcinolone Acetonide 40 mg
- Where
- 37 sites in United States
- Volunteers
- 165 people
- Sponsor
- Swedish Orphan Biovitrum
Asthma; Eosinophilic
Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
This study is aimed at evaluation of the efficacy of mepolizumab 100 mg subcutaneously (SC) every 4 weeks in patients with severe eosinophilic asthma who have been treated for at least 12 months in several Polish allergy/asthma…
- Trial name
- NCT05091385
- Testing
- Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019
- Where
- Poland
- Volunteers
- 106 people
- Sponsor
- Medical University of Lodz
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
Efficacy and safety of imsidolimab (ANB019) in participants with Hidradenitis Suppurativa
- Trial name
- NCT04856930
- Testing
- Imsidolimab
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- Vanda Pharmaceuticals
Osteoarthritis, Knee
Efficacy and Safety of XT-150 in Osteoarthritis of the Knee
This is a Phase 2 safety and efficacy study of XT-150 in adult participants experiencing moderate to severe pain due to osteoarthritis of the knee.
- Trial name
- NCT04124042
- Testing
- XT-150
- Where
- 6 sites in United States, Australia
- Volunteers
- 289 people
- Sponsor
- Xalud Therapeutics, Inc.
Type 2 Diabetes Mellitus
Study of AC-201 in Patients With Type 2 Diabetes Mellitus
This is a 24-week randomized placebo-controlled study to investigate the effect of an oral IL-1beta inhibitor AC-201 in patients with type 2 diabetes mellitus already treated on different background diabetes therapies.
- Trial name
- NCT01276106
- Testing
- AC-201, 25mg, AC-201, 50mg, AC-201, 75mg
- Where
- 21 sites in United States, Taiwan
- Volunteers
- 259 people
- Sponsor
- TWi Biotechnology, Inc.
Bronchiolitis Obliterans Syndrome, Graft Rejection
Azithromycin in Bronchiolitis Obliterans Syndrome
Preventive treatment with azithromycin reduces the prevalence fo Bronchiolitis Obliterans Syndrome after lung transplantation.
- Conditions
- Bronchiolitis Obliterans Syndrome, Graft Rejection, Lymphocytic Bronchiolitis, Respiratory Infection
- Trial name
- AZI001 (NCT01009619)
- Testing
- Azithromycin
- Where
- Belgium
- Volunteers
- 83 people
- Sponsor
- KU Leuven
Chemotherapy-induced Nausea and Vomiting
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
The purpose of this study is to investigate the effectiveness of intravenous fosaprepitant therapy to reduce nausea and vomiting during the treatment of high dose interleukin-2 (HD IL-2) therapy for metastatic melanoma or…
- Trial name
- HDIL2/Emend (NCT01874119)
- Testing
- Fosaprepitant
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- St. Louis University
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00307437
- Testing
- Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
- Where
- 62 sites in United States, Austria and 5 more
- Volunteers
- 1,230 people
- Sponsor
- Centocor Research & Development, Inc.